Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nolatrexed. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nolatrexed SCHEMBL29420099 | 1.00 | TYMS (0.97) | TYMSDHFR | |
| Nolatrexed SCHEMBL27935384 | 1.00 | TYMS (0.97) | TYMSDHFR | |
| Nolatrexed SCHEMBL710461 | 0.99 | TYMS (1.00) | TYMSDHFR | |
| SCHEMBL7826662 | 0.86 | TYMS (1.00) | TYMS | |
| Nolatrexed SCHEMBL18489 | 0.79 | TYMS (0.66) | TYMSDHFR | |
| Nolatrexed SCHEMBL1649851 | 0.78 | TYMS (0.65) | TYMSDHFR | |
| SCHEMBL16807869 | 0.75 | TYMS (0.61) | TYMSDHFR | |
| SCHEMBL7827130 | 0.73 | TYMS (1.00) | TYMSDHFR | |
| SCHEMBL7831197 | 0.72 | TYMS (1.00) | TYMSDHFR | |
| SCHEMBL27555186 | 0.71 | TYMS (0.58) | TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130855-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-05-14 | — | — | US | claimed |
| US-20250319188-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2025-10-16 | — | — | US | claimed |
| US-20250319123-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2025-10-16 | — | — | US | claimed |
| US-20250161455-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2025-05-22 | — | — | US | claimed |
| US-20250082575-A1 | GAMMA POLYGLUTAMATED PRALATREXATE AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2025-03-13 | — | — | US | claimed |
| US-12220431-B2 | Gamma polyglutamated antifolates and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2025-02-11 | — | — | US | claimed |
| US-12076402-B2 | Alpha polyglutamated antifolates and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2024-09-03 | — | — | US | claimed |
| US-12048767-B2 | Gamma polyglutamated pralatrexate and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2024-07-30 | — | — | US | claimed |
| WO-2026106969-A1 | NOVEL INHIBITORS OF INTERLEUKIN RECEPTOR- ASSOCIATED KINASE | UNIVERSITY OF ROCHESTER (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026107349-A1 | HETEROCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASES | ANTARES THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260130855-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12624117-B2 | Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides | THE GENERAL HOSPITAL CORPORATION (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4735116-A2 | ANTI-TRAILR2 ANTIGEN-BINDING PROTEINS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-3244930-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIV SOUTHERN CALIFORNIA (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20080161578-A1 | 8-bromo-2-[(3-hydroxyphenylamino)methyl]-3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-one; increasing cell death of cancer cells, limiting tumor growth, decreasing metastasis, and prolonging the survival of tumor-bearing animals | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
| CN-101132783-A | Apogossypolone and the uses thereof | UNIV MICHIGAN (US) | 2008-02-27 | — | — | CN | disclosed |
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | ABBVIE INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2007079164-A2 | PROTEIN KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007067781-A2 | 9-MEMBERED HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070135387-A1 | Inhibitors of protein kinases | ABBOTT LABORATORIES | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12048767-B2 | Gamma polyglutamated pralatrexate and uses thereof | IFNG, GMFG, IL2 | TYMS 38/4885DHFR 30/4885 |
| US-12220431-B2 | Gamma polyglutamated antifolates and uses thereof | GGCT, IFNG, FPGS | TYMS 62/4885DHFR 14/4885 |
| US-20250319123-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | GGCT, IFNG, FPGS | TYMS 62/4885DHFR 14/4885 |
| US-12624117-B2 | Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides | TNFRSF9, TNFRSF1A, TNFSF11 | TYMS 2523/4885DHFR 1175/4885 |
| US-20250082575-A1 | GAMMA POLYGLUTAMATED PRALATREXATE AND USES THEREOF | IFNG, GMFG, IL2 | TYMS 38/4885DHFR 30/4885 |
| US-20080161578-A1 | 8-bromo-2-[(3-hydroxyphenylamino)methyl]-3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-one; increasing cell death of cancer cells, limiting tumor growth, decreasing metastasis, and prolonging the survival of tumor-bearing animals | PIM1, PIM2, PIM3 | TYMS 563/4885DHFR 1270/4885 |
| US-20250161455-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | FPGS, GGCT, FOLR1 | TYMS 68/4885DHFR 6/4885 |
| US-12076402-B2 | Alpha polyglutamated antifolates and uses thereof | FPGS, GGCT, FOLR1 | TYMS 68/4885DHFR 6/4885 |
| US-20070135387-A1 | Inhibitors of protein kinases | MAP3K20, PACSIN2, MAP4K2 | TYMS 1315/4885DHFR 1568/4885 |
| US-20250319188-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | FPGS, GGCT, FOLR1 | TYMS 68/4885DHFR 6/4885 |
| US-20260130855-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | FOLR2, FPGS, FOLR1 | TYMS 16/4885DHFR 41/4885 |
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | PACSIN2, MAP3K20, PHKG1 | TYMS 1716/4885DHFR 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.